"Cash expenditure for the next 2 quarters is forecast to be lower than those incurred during the last 2 quarters. Decreased expenditure in the next 2 quarters will be primarily in clinical trials, CE Mark approval for sale and inventory manufacturing costs, all incurred to establish initial inventory and the start of sales in the EU."
June 30 cash burn was ~2.8 mil Sept 30 cash burn was ~2.5 mil
From the Sept 30 cash flow statement ~1 mil was spent on research and inventory (0.8 and 0.2 respectively), whilst a new item called "manufacturing control and compliance, including process characterisation and stability studies for global regulatory compliance" was added; which was ~0.5 mil.
Essentially i'm cautious about TISs ability to reduce total expenditure particularly as research costs cannot be cut to zero as it may result in the permanent loss of specialised research staff that are necessary for TISs future.
TIS Price at posting:
38.0¢ Sentiment: LT Buy Disclosure: Not Held
